Europe

AbbVie's blockbuster hopeful Rinvoq, J&J's Spravato eye EU rollouts, thanks to new backing
AbbVie's blockbuster hopeful Rinvoq, J&J's Spravato eye EU rollouts, thanks to new backing
Fierce Pharma
AbbVie
Rinvoq
Europe
JNJ
Spravato
Flag link:
Eli Lilly to voluntarily delist from Euronext Paris exchange
Eli Lilly to voluntarily delist from Euronext Paris exchange
Marketwatch
Eli Lilly
Europe
Flag link:
Takeda eyes emerging markets asset sale to trim its debt; report
Takeda eyes emerging markets asset sale to trim its debt; report
Pharmaforum
Takeda
Shire
M&A
emerging markets
Europe
Flag link:
GW Pharma's cannabis-derived epilepsy medicine makes the cut in the European Union
GW Pharma's cannabis-derived epilepsy medicine makes the cut in the European Union
Endpoints
GW Pharma
Europe
Epidyolex
Epidiolex
Flag link:
European biotech firm BioNtech plans to raise nearly $304 mln in U.S. IPO
European biotech firm BioNtech plans to raise nearly $304 mln in U.S. IPO
Yahoo/Reuters
Europe
IPOs
BioNTech
MRNA
Flag link:
Bayer’s Vitrakvi is first tumour-agnostic drug approved in EU
Bayer’s Vitrakvi is first tumour-agnostic drug approved in EU
Pharmaforum
Bayer
TRK inhibitors
Vitrakvi
Europe
tumor agnostic drugs
cancer
Flag link:
Astellas maintains lead over Daiichi Sankyo with CHMP okay for Xospata
Astellas maintains lead over Daiichi Sankyo with CHMP okay for Xospata
Pharmaforum
Astellas
AML
Xospata
Europe
Daiichi Sankyo
Flag link:
Biotechs Fly Sideways In Quiet Week — 5 News Items You May Have Missed
Biotechs Fly Sideways In Quiet Week — 5 News Items You May Have Missed
Investors Business Daily
Wave Life Sciences
suvodirsen
DMD
Merck
Keytruda
Biogen
Spinraza
Zoetis
Europe
animal health
Jazz Pharmaceuticals
JZP-258
narcolepsy
Flag link:
Astellas' AML drug wins over CHMP — strengthening lead on Daiichi Sankyo
Astellas' AML drug wins over CHMP — strengthening lead on Daiichi Sankyo
Endpoints
Astellas
FDA
gilteritinib
Europe
AML
Daiichi Sankyo
Flag link:
Evidence underpinning approval of new cancer drugs raises questions
Evidence underpinning approval of new cancer drugs raises questions
Medical Express
Europe
cancer
oncology
drug approvals
bias
Flag link:
J&J gets Stelara okay in Europe for ulcerative colitis
J&J gets Stelara okay in Europe for ulcerative colitis
Pharmaforum
JNJ
Stelara
Janssen
Europe
Flag link:
Roche boosts cancer approvals in Europe, pushing for a bigger slice of the I/O pie
Roche boosts cancer approvals in Europe, pushing for a bigger slice of the I/O pie
Endpoints
Roche
Europe
non-squamous cell non-small cell lung cancer
Tecentriq
Flag link:
Keytruda combo cleared as first-line kidney cancer treatment in EU
Keytruda combo cleared as first-line kidney cancer treatment in EU
Pharmaforum
Merck
Keytruda
kidney cancer
Europe
Flag link:
ESC: New Pfizer, BMS real-world data could boost Eliquis in Europe
ESC: New Pfizer, BMS real-world data could boost Eliquis in Europe
Fierce Pharma
Pfizer
Bristol-Myers Squibb
Eliquis
Warfarin
bloodthinners
Europe
ESC
European Society of Cardiology
Flag link:
EMA follows FDA to approve Roche's Tecentriq combo for frontline use in triple negative breast cancer
EMA follows FDA to approve Roche's Tecentriq combo for frontline use in triple negative breast cancer
Endpoints
Roche
Tecentriq
FDA
Europe
Celgene
Abraxane
triple negative breast cancer
Flag link:
Bristol-Myers, AbbVie's multiple myeloma drug wins second EU nod as part of triple regimen
Bristol-Myers, AbbVie's multiple myeloma drug wins second EU nod as part of triple regimen
Endpoints
Bristol-Myers Squibb
AbbVie
Empliciti
Celgene
Europe
relapsed or refractory multiple myeloma
Flag link:
Lilly faces biosimilar rivals to osteoporosis drug Forsteo in Europe
Lilly faces biosimilar rivals to osteoporosis drug Forsteo in Europe
Pharmaforum
Eli Lilly
biosimilars
osteoporosis
Forsteo
Europe
Stada
Gedeon Richter
Flag link:
EMA and FDA Historically Agree on Just About Every New Drug Approval, but is That Slowly Changing?
EMA and FDA Historically Agree on Just About Every New Drug Approval, but is That Slowly Changing?
RAPS.org
FDA
EMA
Europe
drug approvals
Flag link:
Brexit's Disruptive Impact On U.K. And European Prescription Drug Market
Brexit's Disruptive Impact On U.K. And European Prescription Drug Market
Forbes
Brexit
UK
Europe
Flag link:
Janssen gets EC approval for two new indications of Imbruvica
Janssen gets EC approval for two new indications of Imbruvica
Pharmaceutical Business Review
JNJ
Janssen
Europe
Imbruvica
Waldenström’s macroglobulinemia
chronic lymphocytic leukemia
Flag link:

Pages